Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NANOCRISPR

Financiado

Cerrado

NANODELIVERY OF SPECIFIC GENOME ENGINEERING TOOLS AS A NOVEL THERAPEUTIC APPROAC...

NANODELIVERY OF SPECIFIC GENOME ENGINEERING TOOLS AS A NOVEL THERAPEUTIC APPROACH FOR AGGRESSIVE PROSTATE CANCERS Prostate cancer is the second most common diagnosed malignancy and the fifth leading cause of cancer mortality in men. Whilst primary tumours respond well to therapy, tumours in the metastatic setting become inherently resistant t... ver más

10/01/2023

UCLM

173K€

Presupuesto del proyecto: 173K€

Líder del proyecto

UNIVERSIDAD DE CASTILLA-LA MANCHA No se ha especificado una descripción o un objeto social para esta compañía.

Total investigadores 2590

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-01-10

MSCA-IF-2019: Individual Fellowships

I+D

Cerrada hace 5 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UCLM

172.93K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2017-89288-R TERAPIA GENICA EN GLIOBLASTOMA: UN NUEVO ABORDAJE TERAPEUTIC... 145K€ Cerrado

PID2020-120134RB-I00 NANOPARTICULAS Y SIRNA: UNA NUEVA FARMACOTERAPIA PARA EL GLI... 254K€ Cerrado

NANO-ENGINE A revolutionary cell programming platform based on the targe... 3M€ Cerrado

SAF2017-87305-R NANOESTRUCTURAS INTELIGENTES CONTRA EL MELANOMA DE UVEA Y EL... 121K€ Cerrado

PREVENT Prostate cancer extracellular vesicles as biomarkers for nan... 228K€ Cerrado

CPP2021-008946 New protein-based nanodrugs for the development of targeted... 616K€ Cerrado

Duración del proyecto: 34 meses Fecha Inicio: 2020-03-04
Fecha Fin: 2023-01-10

Líder del proyecto

UNIVERSIDAD DE CASTILLA-LA MANCHA No se ha especificado una descripción o un objeto social para esta compañía.

Total investigadores 2590

Presupuesto del proyecto 173K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Prostate cancer is the second most common diagnosed malignancy and the fifth leading cause of cancer mortality in men. Whilst primary tumours respond well to therapy, tumours in the metastatic setting become inherently resistant to chemotherapy. Thus, more novel and effective therapeutic approaches are highly needed to treat this lethal disease. The cornerstone treatment for advanced prostate cancer consists of androgen deprivation therapy and docetaxel (DTX). However, both DTX activity and Androgen receptor (AR) signalling are highly interrelated. On the one hand, it has been shown that DTX is able to inhibit Androgen Receptor (AR) signalling and on the other hand, the activation of AR signaling can induce DTX insensitivity. In order to break this dependency of DTX effectiveness on AR signaling and ensure efficient treatment for advanced prostate cancer, we propose the selective inhibition of AR deploying CRISPR/Cas9 technology together with DTX. Both therapeutical approaches will be encapsulated into prostate-specific targeted nanoparticles which will allow the simultaneous delivery of the drug and CRISPR plasmids targeting AR into the tumour site. The designed state-of-art multi-functional nanoparticles will reprogram and sensitise the prostate tumour to DTX in situ, and will also induce a higher accumulation of the treatment in the tumour while healthy tissues will remain less affected. Moreover, the use of CRISPR/Cas9 will precisely engineer the prostate cancer cells to express lower levels of AR, contrasting with current anti-AR treatments, which have multiple off-targets. This approach represents an innovative targeted therapy for advanced prostate cancer. It will allow the administration of lower doses of chemotherapy with consequently reduced toxicity and the potential for longer tolerated treatment periods, whilst improving efficacy by selectively suppressing the molecular pathways causing cancer survival and resistance to treatment.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores